BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22261803)

  • 1. Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases.
    de Miranda NF; Goudkade D; Jordanova ES; Tops CM; Hes FJ; Vasen HF; van Wezel T; Morreau H
    Clin Cancer Res; 2012 Mar; 18(5):1237-45. PubMed ID: 22261803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cells infiltrating colorectal cancer and MHC class I expression.
    Sandel MH; Speetjens FM; Menon AG; Albertsson PA; Basse PH; Hokland M; Nagelkerke JF; Tollenaar RA; van de Velde CJ; Kuppen PJ
    Mol Immunol; 2005 Feb; 42(4):541-6. PubMed ID: 15607811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional CD8+ T cells infiltrate into nonsmall cell lung carcinoma.
    Verdegaal EM; Hoogstraten C; Sandel MH; Kuppen PJ; Brink AA; Claas FH; Gorsira MC; Graadt van Roggen JF; Osanto S
    Cancer Immunol Immunother; 2007 May; 56(5):587-600. PubMed ID: 16924494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.
    Ryschich E; Nötzel T; Hinz U; Autschbach F; Ferguson J; Simon I; Weitz J; Fröhlich B; Klar E; Büchler MW; Schmidt J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):498-504. PubMed ID: 15701833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
    Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance.
    Hilders CG; Munoz IM; Nooyen Y; Fleuren GJ
    Gynecol Oncol; 1995 Jun; 57(3):366-75. PubMed ID: 7774840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.
    Yamada N; Oizumi S; Kikuchi E; Shinagawa N; Konishi-Sakakibara J; Ishimine A; Aoe K; Gemba K; Kishimoto T; Torigoe T; Nishimura M
    Cancer Immunol Immunother; 2010 Oct; 59(10):1543-9. PubMed ID: 20567822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
    Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
    Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between HLA-expression and infiltration of immune cells in cervical carcinoma.
    Hilders CG; Houbiers JG; van Ravenswaay Claasen HH; Veldhuizen RW; Fleuren GJ
    Lab Invest; 1993 Dec; 69(6):651-9. PubMed ID: 8264228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical utility of the local inflammatory response in colorectal cancer.
    Richards CH; Roxburgh CS; Powell AG; Foulis AK; Horgan PG; McMillan DC
    Eur J Cancer; 2014 Jan; 50(2):309-19. PubMed ID: 24103145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.
    Suzuki H; Chikazawa N; Tasaka T; Wada J; Yamasaki A; Kitaura Y; Sozaki M; Tanaka M; Onishi H; Morisaki T; Katano M
    Cancer Immunol Immunother; 2010 May; 59(5):653-61. PubMed ID: 19908042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells.
    Diederichsen AC; Hjelmborg Jv; Christensen PB; Zeuthen J; Fenger C
    Cancer Immunol Immunother; 2003 Jul; 52(7):423-8. PubMed ID: 12695859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.
    Maby P; Tougeron D; Hamieh M; Mlecnik B; Kora H; Bindea G; Angell HK; Fredriksen T; Elie N; Fauquembergue E; Drouet A; Leprince J; Benichou J; Mauillon J; Le Pessot F; Sesboüé R; Tuech JJ; Sabourin JC; Michel P; Frébourg T; Galon J; Latouche JB
    Cancer Res; 2015 Sep; 75(17):3446-55. PubMed ID: 26060019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells.
    Dadabayev AR; Sandel MH; Menon AG; Morreau H; Melief CJ; Offringa R; van der Burg SH; Janssen-van Rhijn C; Ensink NG; Tollenaar RA; van de Velde CJ; Kuppen PJ
    Cancer Immunol Immunother; 2004 Nov; 53(11):978-86. PubMed ID: 15197496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
    Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
    Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Galon J; Costes A; Sanchez-Cabo F; Kirilovsky A; Mlecnik B; Lagorce-Pagès C; Tosolini M; Camus M; Berger A; Wind P; Zinzindohoué F; Bruneval P; Cugnenc PH; Trajanoski Z; Fridman WH; Pagès F
    Science; 2006 Sep; 313(5795):1960-4. PubMed ID: 17008531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
    Riemersma SA; Oudejans JJ; Vonk MJ; Dreef EJ; Prins FA; Jansen PM; Vermeer MH; Blok P; Kibbelaar RE; Muris JJ; Schuuring EM; Kluin PM
    J Pathol; 2005 Jul; 206(3):328-36. PubMed ID: 15887291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.